The preclinical evaluation of avutometinib in combination with panitumumab showed significant antitumor activity in CRC PDX models harboring KRAS mutations, with more tumor regression observed in a KRAS G12V PDX model than in a KRAS G12D model [84]. The gene discussed is KRAS; the disease is neoplasm.